Last reviewed · How we verify
NCT05280600: DANCE-AE
Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
trial testing Not applicable - non-interventional study in Anti-N-Methyl-D-Aspartate Receptor Encephalitis in 75 participants. Status unknown.
28 February 2024
Quick facts
| Lead sponsor | King's College London |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 75 |
| Start date | 19 May 2022 |
| Primary completion | 28 February 2024 |
| Estimated completion | 28 February 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Not applicable - non-interventional study
Conditions studied
- Anti-N-Methyl-D-Aspartate Receptor Encephalitis — all drugs for Anti-N-Methyl-D-Aspartate Receptor Encephalitis →
- Autoimmune Encephalitis — all drugs for Autoimmune Encephalitis →
Sponsor
King's College London
Who can join
Adults 8 to 24, any sex, with Anti-N-Methyl-D-Aspartate Receptor Encephalitis or Autoimmune Encephalitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Autoimmune encephalitis is brain inflammation caused by the immune system mistakenly reacting against proteins in the brain. The commonest form is called NMDAR-antibody encephalitis (N-methyl-D-aspartate receptor antibody encephalitis), a rare condition which mainly affects children and young people and causes difficulties in memory, thinking and mental health which can have significant long-term impacts on education, employment and quality of life. In this project we will use advanced magnetic resonance imaging (MRI) to measure changes in the structure, function and chemistry of the brains of children and young people who are in early recovery from NMDAR-antibody encephalitis and other forms of immune-mediated encephalitis. We will investigate if MRI measurements in patients differ from those in healthy people, and if they can help predict patient outcome one year later, assessed by tests of memory, thinking, mental health and functioning in daily life.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Medical Applications of Molecular Biotechnologies in the Context of Hashimoto's Thyroiditis.
Trovato M, Valenti A. · · 2023 · cited 1× · PMID 37371008 · DOI 10.3390/diagnostics13122114
Verify or expand the search:
- PubMed search for NCT05280600
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Currently open trials in the same condition.
- NCT06510283 — Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis · Phase 2 · recruiting
- NCT06867991 — Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis · Phase 3 · recruiting
Other King's College London trials
Trials by the same sponsor.
- NCT07357064 — Professional Decision Making in Childbirth. · not yet recruiting
- NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
- NCT07228962 — Cutaneous Biomarkers in Atopic Eczema Using a Non-Invasive Micro-Suction Device in Babies · not yet recruiting
- NCT07365722 — Comparison of Two Non-surgical Procedure to Manage Gum Disease Around Implants. · NA · not yet recruiting
- NCT07378488 — Dance/Movement Therapy for Functional Neurological Disorder · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05280600 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by King's College London
- Last refreshed: 6 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05280600.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing